Capital Fund Management (CFM)
ALXN

Capital Fund Management (CFM)’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Fund Management (CFM)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,900
Closed -$1.88M – 1722
2020
Q1 		$1.88M Buy
+20,900
New +$2.05M 0.03% 550
2019
Q3 		– Sell
-3,600
Closed -$472K – 1980
2019
Q2 		$472K Buy
+3,600
New +$464K ﹤0.01% 1238
2016
Q2 		– Sell
-5,100
Closed -$710K – 1875
2016
Q1 		$710K Buy
+5,100
New +$749K 0.01% 1008
2015
Q2 		– Sell
-1,300
Closed -$225K – 1767
2015
Q1 		$225K Sell
1,300
-400
-24% -$72.4K ﹤0.01% 1339
2014
Q4 		$315K Sell
1,700
-400
-19% -$74.1K ﹤0.01% 1319
2014
Q3 		$348K Sell
2,100
-17,100
-89% -$2.81M ﹤0.01% 1273
2014
Q2 		$3M Buy
19,200
+12,900
+205% +$2.04M 0.03% 590
2014
Q1 		$958K Sell
6,300
-7,000
-53% -$1.11M 0.01% 974
2013
Q4 		$1.77M Sell
13,300
-17,700
-57% -$2.12M 0.02% 744
2013
Q3 		$3.6M Sell
31,000
-300
-1% -$32.9K 0.05% 447
2013
Q2 		$2.89M Buy
+31,300
New +$3.02M 0.04% 510

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s ALXN Position: Q3 2020 in Review

Capital Fund Management (CFM) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 49,084 shares — an estimated $5.51M sold.

Capital Fund Management (CFM) first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $58.2M in Q2 2017. 708 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Capital Fund Management (CFM) reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 49,084 Alexion Pharmaceuticals shares in Q3 2020, an estimated $5.51M.
  • Capital Fund Management (CFM) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Capital Fund Management (CFM)'s Alexion Pharmaceuticals position peaked at $58.2M in Q2 2017.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2020, filed 13 Nov 2020.